No Data
No Data
The Arbitration Panel Issued A Final Award Which Found And Concluded That Aadi Bioscience Did Not Breach The EOC Pharma License Agreement And Accordingly Is Not Liable For Any Damages To EOC - Filing
Aadi Bioscience Downgraded to Neutral, Shares Fall
Aadi Bioscience Price Target Cut to $1.75/Share From $5.00 by Piper Sandler
Piper Sandler Downgrades Aadi Biosciences(AADI.US) to Hold Rating, Cuts Target Price to $1.75
Piper Sandler analyst Joseph Catanzaro downgrades $Aadi Biosciences(AADI.US)$ to a hold rating, and adjusts the target price from $5 to $1.75.According to TipRanks data, the analyst has a success
Piper Sandler Downgrades Aadi Bioscience to Neutral From Overweight
Express News | Aadi Bioscience Inc : Piper Sandler Cuts to Neutral From Overweight